Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CMP-N-acetylneuraminate + 1-deoxy-1-cholesteryl (N-acetyl)-ethanolaminolactitol
CMP + ?
-
115% of activity with lactosylceramide
-
-
?
CMP-N-acetylneuraminate + 1-deoxy-1-cholesterylethanolaminolactitol
CMP + ?
-
28% of activity with lactosylceramide
-
-
?
CMP-N-acetylneuraminate + 1-deoxy-1-cholesterylphospho (N-acetyl)-ethanolaminolactitol
CMP + ?
-
151% of activity with lactosylceramide
-
-
?
CMP-N-acetylneuraminate + 1-deoxy-1-cholesterylphosphoethanolaminolactitol
CMP + ?
-
60% of activity with lactosylceramide
-
-
?
CMP-N-acetylneuraminate + 2,3-dicholesteryl-1-beta-lactosylglycerol
?
-
113% of activity with lactosylceramide
-
-
?
CMP-N-acetylneuraminate + 2-cholesteryl-1-beta-lactosylglycerol
?
-
138% of activity with lactosylceramide
-
-
?
CMP-N-acetylneuraminate + 3-cholesteryl-1-beta-lactosylglycerol
?
-
163% of activity with lactosylceramide
-
-
?
CMP-N-acetylneuraminate + asialoGM1
?
-
27.7% relative activity to lactosylceramide
-
-
?
CMP-N-acetylneuraminate + asialoGM1
CMP + GM1
-
-
-
?
CMP-N-acetylneuraminate + asialoGM2
CMP + GM2
-
-
-
?
CMP-N-acetylneuraminate + beta-D-galactosyl-1,3-N-acetylgalactosamin-1,4-beta-D-galactosyl-1,4-beta-D-glucosylceramide
CMP + ?
-
i.e. asialo-ganglioside GM1, sialylated at about 84% the rate of lactosylceramide
-
-
?
CMP-N-acetylneuraminate + beta-D-galactosyl-1,3-N-acetylgalactosamin-lactosylceramide
CMP + ?
-
14% of activity with lactosylceramide
-
-
?
CMP-N-acetylneuraminate + beta-D-galactosyl-1,4-beta-D-glucosylceramide
CMP + N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosylceramide
CMP-N-acetylneuraminate + beta-lactosylcholesterol
?
-
138% of activity with lactosylceramide
-
-
?
CMP-N-acetylneuraminate + cholesteryl-beta-lactosylpropane-1,3-diol
?
-
143% of activity with lactosylceramide
-
-
?
CMP-N-acetylneuraminate + galactosylceramide
?
-
30% relative activity to lactosylceramide
-
-
?
CMP-N-acetylneuraminate + galactosylceramide
CMP + ?
-
sialylated at about 40% the rate of lactosylceramide
-
-
?
CMP-N-acetylneuraminate + galactosylceramide
CMP + alpha-N-acetylneuraminyl-2,3-beta-D-galactosyl-ceramide
-
-
-
?
CMP-N-acetylneuraminate + glucosylceramide
CMP + ?
-
sialylated at about 65% the rate of lactosylceramide
-
-
?
CMP-N-acetylneuraminate + GM3
?
-
4.5% relative activity to lactosylceramide
-
-
?
CMP-N-acetylneuraminate + lactosylceramide
?
-
100% relative activity
-
-
?
CMP-N-acetylneuraminate + lactosylceramide
CMP + alpha-N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosyl-ceramide
CMP-N-acetylneuraminate + lactosylceramide
CMP + N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosylceramide
CMP-Neu5Ac + lactosylceramide
?
-
caveolin-1 is a GM3-interacting protein in GM3 synthase overexpressing cells
-
-
?
additional information
?
-
CMP-N-acetylneuraminate + beta-D-galactosyl-1,4-beta-D-glucosylceramide
CMP + N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosylceramide
-
-
i.e. ganglioside GM3
?
CMP-N-acetylneuraminate + beta-D-galactosyl-1,4-beta-D-glucosylceramide
CMP + N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosylceramide
-
-
i.e. ganglioside GM3
?
CMP-N-acetylneuraminate + beta-D-galactosyl-1,4-beta-D-glucosylceramide
CMP + N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosylceramide
-
-
i.e. ganglioside GM3
?
CMP-N-acetylneuraminate + beta-D-galactosyl-1,4-beta-D-glucosylceramide
CMP + N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosylceramide
-
-
i.e. ganglioside GM3
?
CMP-N-acetylneuraminate + beta-D-galactosyl-1,4-beta-D-glucosylceramide
CMP + N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosylceramide
-
-
i.e. ganglioside GM3
?
CMP-N-acetylneuraminate + beta-D-galactosyl-1,4-beta-D-glucosylceramide
CMP + N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosylceramide
-
-
-
-
?
CMP-N-acetylneuraminate + beta-D-galactosyl-1,4-beta-D-glucosylceramide
CMP + N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosylceramide
-
-
i.e. ganglioside GM3
-
CMP-N-acetylneuraminate + beta-D-galactosyl-1,4-beta-D-glucosylceramide
CMP + N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosylceramide
-
-
i.e. ganglioside GM3
?
CMP-N-acetylneuraminate + beta-D-galactosyl-1,4-beta-D-glucosylceramide
CMP + N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosylceramide
-
-
i.e. ganglioside GM3
?
CMP-N-acetylneuraminate + beta-D-galactosyl-1,4-beta-D-glucosylceramide
CMP + N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosylceramide
-
-
i.e. ganglioside GM3
-
CMP-N-acetylneuraminate + beta-D-galactosyl-1,4-beta-D-glucosylceramide
CMP + N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosylceramide
-
-
i.e. ganglioside GM3
?
CMP-N-acetylneuraminate + beta-D-galactosyl-1,4-beta-D-glucosylceramide
CMP + N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosylceramide
-
-
i.e. ganglioside GM3
?
CMP-N-acetylneuraminate + beta-D-galactosyl-1,4-beta-D-glucosylceramide
CMP + N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosylceramide
-
-
i.e. ganglioside GM3
?
CMP-N-acetylneuraminate + beta-D-galactosyl-1,4-beta-D-glucosylceramide
CMP + N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosylceramide
-
-
i.e. ganglioside GM3
?
CMP-N-acetylneuraminate + beta-D-galactosyl-1,4-beta-D-glucosylceramide
CMP + N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosylceramide
-
-
i.e. ganglioside GM3
?
CMP-N-acetylneuraminate + beta-D-galactosyl-1,4-beta-D-glucosylceramide
CMP + N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosylceramide
-
-
i.e. ganglioside GM3
?
CMP-N-acetylneuraminate + beta-D-galactosyl-1,4-beta-D-glucosylceramide
CMP + N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosylceramide
-
-
i.e. ganglioside GM3
?
CMP-N-acetylneuraminate + beta-D-galactosyl-1,4-beta-D-glucosylceramide
CMP + N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosylceramide
-
-
i.e. ganglioside GM3
?
CMP-N-acetylneuraminate + beta-D-galactosyl-1,4-beta-D-glucosylceramide
CMP + N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosylceramide
-
-
i.e. ganglioside GM3
?
CMP-N-acetylneuraminate + beta-D-galactosyl-1,4-beta-D-glucosylceramide
CMP + N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosylceramide
-
i.e. lactosylceramide, high specificity
i.e. ganglioside GM3
?
CMP-N-acetylneuraminate + beta-D-galactosyl-1,4-beta-D-glucosylceramide
CMP + N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosylceramide
-
preferred acceptors have the general structure beta1-O-ceramide, disaccharides are preferred to monosaccharide
i.e. ganglioside GM3
?
CMP-N-acetylneuraminate + beta-D-galactosyl-1,4-beta-D-glucosylceramide
CMP + N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosylceramide
-
no acceptors are fetuin, mucin, alpha1-acid glycoprotein, glycophorin or their respective asialo-derivatives, gangliosides GD1b, GM3, GM2, GM1 or GD1a
i.e. ganglioside GM3
?
CMP-N-acetylneuraminate + beta-D-galactosyl-1,4-beta-D-glucosylceramide
CMP + N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosylceramide
-
brain sialyltransferase shows high activity with d18:1-16:0, d18:1-22:1, and d18:0-18:0 lactosylceramide molecular species, specificity changes when the lipid composition of the neuronal microsomal membrane resembles that of liver Golgi membrane lipids
i.e. ganglioside GM3
-
CMP-N-acetylneuraminate + beta-D-galactosyl-1,4-beta-D-glucosylceramide
CMP + N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosylceramide
-
-
i.e. ganglioside GM3
?
CMP-N-acetylneuraminate + lactosylceramide
CMP + alpha-N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosyl-ceramide
-
-
-
?
CMP-N-acetylneuraminate + lactosylceramide
CMP + alpha-N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosyl-ceramide
-
-
-
-
?
CMP-N-acetylneuraminate + lactosylceramide
CMP + alpha-N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosyl-ceramide
-
metabolic flux and expression levels of enzymes involved in the sialic acid biosynthetic pathway, overview
-
-
?
CMP-N-acetylneuraminate + lactosylceramide
CMP + alpha-N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosyl-ceramide
-
-
-
-
?
CMP-N-acetylneuraminate + lactosylceramide
CMP + alpha-N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosyl-ceramide
-
ganglioside GM3 is involved in neuronal cell death
-
-
?
CMP-N-acetylneuraminate + lactosylceramide
CMP + N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosylceramide
-
synthesizes the first ganglioside of the gangliotetraose series, GM3
-
-
-
CMP-N-acetylneuraminate + lactosylceramide
CMP + N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosylceramide
-
-
-
?
CMP-N-acetylneuraminate + lactosylceramide
CMP + N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosylceramide
-
involved in sequential addition of monosaccharides from sugar nucleotides to non-reducing end of oligosaccharide chains of glycosphingolipids
-
-
-
additional information
?
-
-
the cAMP responsive element binding protein binding site of the hST3Gal V promoter plays a critical role in transcriptional regulation of the hST3Gal V gene during HL-60 cell differentiation
-
-
-
additional information
?
-
-
upregulation of GM3 synthase through protein kinase C/extracellular regulated kinases-dependent cAMP-responsive element binding protein activation results in the differentiation of HL-60 cells by inducing expression of CD11b
-
-
-
additional information
?
-
-
overexpression of recombinant UDP-GlcNAc 2-epimerase/ManNAc 6-kinase, GNE, in HEK AD293 cells up-regulates GM3 synthase, while GNE down-regulation by RNA interference or exogenous GM3 and GD3 down-regulates the GM3 synthase
-
-
-
additional information
?
-
-
substrate specificity of isozymes, no activity with GD3 and GM1a as acceptors, overview
-
-
-
additional information
?
-
substrate specificity of isozymes, no activity with GD3 and GM1a as acceptors, overview
-
-
-
additional information
?
-
-
no acitvity with GM1 or asialofetuin as acceptor
-
-
-
additional information
?
-
-
the -177 to -83 region, which contains a cAMP-responsive element at -143, functions as the valproic acid-inducible promoter by actively binding cAMP-responsive element binding protein. The cAMP-responsive element at -143 is crucial for the valproic acid-induced expression of hST3Gal V in SK-NBE(2)-C cells
-
-
-
additional information
?
-
-
mice with a disrupted gene encoding GM3 synthase have an enhanced phosphorylation of the skeletal muscle insulin receptor after ligand binding. They show heightened responses in glucose and insulin tolerance tests. The mutant mice are protected from high-fat diet induced insulin resistance
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(4-Amidinophenyl)-methanesulfonyl fluoride
-
serine protease, 0.02 mM, 48% inhibition of purified sialyltransferase-1
alpha2-Macroglobulin
-
1 unit, 67% inhibition of purified sialyltransferase-1, no inhibition of sialyltransferase-1 activity in microsomes
-
Aprotinin
-
serine protease inhibitor, 0.0003 mM, 74% inhibition of purified sialyltransferase-1
dithiothreitol
-
0.1 mM, 89% inhibition of purified sialyltransferase-1
DL-threo-phenyl-2-hexadecanoylamino-3-pyrrolidino-1-propanol
-
inhibitor of ganglioside synthesis, depletion of GM3 synthesis in cultured monocyte-derived macrophages, delays acquisition of CD206 antigen, prevents loss of CD163 antigen and enhances anti-inflammatory cytokine (CCL18) secretion
E-64
-
thiol protease inhibitor, 0.0028 mM, 71% inhibition of purified sialyltransferase-1, activation of sialytransferase-1 activity in microsomes
EDTA
-
0.1 mM, 71% inhibition of purified sialyltransferase-1
Ep-475
-
thiol protease inhibitor, 0.0028 mM, 75% inhibition of purified sialyltransferase-1; thiol protease inhibitor, 0.0028 mM, 84% inhibition of purified sialyltransferase-1
ganglioside GM3
-
0.5 mM and 1 mM, 43% and 60% inhibition respectively
Globotetraosylceramide
-
weak
Go6976
-
protein kinase C inhibitor, treatment of phorbol 12-myristate 13-acetate induced cells reduces expression of GM3 synthase
L-1-chloro-3-[4-tosylamido]-4-phenyl-2-butanone
-
chymotrypsin and thiol protease inhibitor, 0.284 mM, 67% inhibition of purified sialyltransferase-1
L-1-Chloro-3-[4-tosylamido]-7-amino-2-heptanone-HCl
-
trypsin and thiol protease inhibitor, 0.135 mM, 73% inhibition of purified sialyltransferase-1
Leupeptin
-
serine and thiol protease inhibitor, 0.001 mM, 72% inhibition of purified sialyltransferase-1, no inhibition of sialyltransferase-1 activity in microsomes
Monoclonal antibody M12GC7
-
-
-
N3-
-
1 mM, 87% inhibition of purified sialyltransferase-1
pepstatin A
-
0.001 mM, 72% inhibition of purified sialyltransferase-1, activation of sialyltransferase-1 activity in microsomes
Triton CF-54
-
at higher concentrations
U0126
-
extracellular signal-regulated kinase inhibitor, treatment of phorbol 12-myristate 13-acetate induced cells reduces expression of GM3 synthase
UDP-N-acetylgalactosamine
-
weak
CMP
-
-
Zn2+
-
weak
Zn2+
-
10 mM, 90% inhibition
additional information
-
not inhibited by N-ethylmaleimide
-
additional information
-
not inhibited by EDTA
-
additional information
-
overexpression of recombinant UDP-GlcNAc 2-epimerase/ManNAc 6-kinase, GNE, in HEK AD293 cells up-regulates GM3 synthase, while GNE down-regulation by RNA interference or exogenous GM3 and GD3 down-regulates the GM3 synthase
-
additional information
-
motility of low GM3 synthase expressing cells is reduced in the presence of a Src kinase inhibitor
-
additional information
-
glucosylceramide or globotriaosylceramide
-
additional information
-
not inhibited by EDTA; not inhibited by Fe2+, Mg2+, IAA, 2-mercaptoethanol
-
additional information
-
inhibition in vivo i.e. stable microsomes not as dramatic as in vitro
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
-
expression of GM3S mRNA is greater in the highly metastatic 4T1 tumor cells than in the nonmetastatic 67NR cells
brenda
-
-
brenda
-
-
brenda
-
in atherosclerosis, excessive GM3 is synthesized in atherosclerotic lesions by macrophages and dendritic cells directly within the arterial walls in blood arteries additionally to the GM3 synthesis in blood plasma, the fatty acid compositions of GM3 from blood plasma low density lipoprotein and from atherosclerotic lesions differ; level of GM3 synthase in membrane-fractions isolated from the atherosclerotic intima are higher compared to those in non-dieased arterial tissue
brenda
-
in atherosclerosis, excessive GM3 is synthesized in atherosclerotic lesions by macrophages and dendritic cells directly within the arterial walls in blood vessels additionally to the GM3 synthesis in blood plasma, the fatty acid compositions of GM3 from blood plasma low density lipoprotein and from atherosclerotic lesions differ
brenda
-
-
brenda
-
-
brenda
-
; excessive GM3 is synthesized in atherosclerotic lesions by macrophages and dendritic cells directly within the arterial walls
brenda
-
contact-inhibited cell-line NIL-8
brenda
-
high transcript level of SAT-Ia and SAT-Ib transcript
brenda
-
-
brenda
-
strain R, elevated enzyme level if cultured in butyrate containing media
brenda
-
-
brenda
-
-
brenda
-
high levels of SAT-Ia-1 and SAT-Ia-2, whereas very low levels of SAT-Ib-1 and SAT-Ib-2
brenda
-
-
brenda
-
-
brenda
-
murine neuroblastoma x rat dorsal root ganglion F-11A cells
brenda
-
high levels of SAT-Ia-1 and SAT-Ia-2, whereas very low levels of SAT-Ib-1 and SAT-Ib-2
brenda
-
embryonic carcinoma cell line P19 differentiates into neurons and astrocytes on cell aggregation after treatment with retinoic acid
brenda
-
-
brenda
type 5 isozyme
brenda
-
-
brenda
-
high levels of SAT-Ia-1 and SAT-Ia-2, whereas very low levels of SAT-Ib-1 and SAT-Ib-2
brenda
-
high levels of SAT-Ia-1 and SAT-Ia-2, whereas very low levels of SAT-Ib-1 and SAT-Ib-2
brenda
-
high levels of SAT-Ia-1 and SAT-Ia-2, whereas very low levels of SAT-Ib-1 and SAT-Ib-2
brenda
-
level of GM3 synthase in membrane-fractions isolated from the atherosclerotic intima are higher compared to those in non-dieased arterial tissue
brenda
-
atherosclerotic aortic intima
brenda
-
atherosclerotic and normal aorta
brenda
-
-
brenda
-
-
brenda
fetal, isozymes type 1-4
brenda
-
high levels of SAT-Ia-1 and SAT-Ia-2, whereas very low levels of SAT-Ib-1 and SAT-Ib-2
brenda
-
-
brenda
-
three SAT-I isoforms, high transcript level of SAT-Ia and SAT-Ib transcript
brenda
-
-
brenda
-
-
brenda
-
-
-
brenda
-
-
brenda
-
phorbol myristate actetate-stimulated
brenda
-
the cAMP responsive element binding protein binding site of the hST3Gal V promoter plays a critical role in transcriptional regulation of the hST3Gal V gene during HL-60 cell differentiation
brenda
-
upregulation of GM3 synthase through protein kinase C/extracellular regulated kinases-dependent cAMP-responsive element binding protein activation results in the differentiation of HL-60 cells by inducing expression of CD11b
brenda
type 2 isozyme
brenda
-
GM3 synthase expression analysis, the enzyme is expressed during the induction of megakaryocytic differentiation in human leukemia K562 cells by phorbol 12-myristate 13-acetate depending upon the PKC/ERK/CREB pathway, overview
brenda
-
treatment of phorbol 12-myristate 13-acetate induced cells with protein kinase C inhibitor Go6976 or extracellular signal-regulated kinase inhibitor U0126 reduces expression of GM3 synthase. Activation of extracellular signal-regulated kinase and cAMP response element binding protein is prevented by pretreatment with Go6976 and U0126
brenda
-
-
brenda
-
-
brenda
-
from peripheral blood mononuclear cells, enzyme level is stimulated by growth in the presence of phytohemagglutinin
brenda
-
-
brenda
-
; excessive GM3 is synthesized in atherosclerotic lesions by macrophages and dendritic cells directly within the arterial walls
brenda
-
differentiated monocyte-derived macrophages
brenda
-
-
brenda
-
brain neuron
brenda
-
high levels of SAT-Ia-1 and SAT-Ia-2, whereas very low levels of SAT-Ib-1 and SAT-Ib-2
brenda
-
high transcript level of SAT-Ia and SAT-Ib transcript
brenda
-
high levels of SAT-Ia-1 and SAT-Ia-2, whereas very low levels of SAT-Ib-1 and SAT-Ib-2
brenda
-
the GM3 synthase gene is expressed at relatively higher levels in the dexamethasone-administered mice than in the control mice
brenda
additional information
-
immunohistochemic analysis of tissue distribution of GM3 synthase
brenda
additional information
-
SK-N-BE(2)-C neuroblastoma cell
brenda
additional information
-
in cervix, high levels of SAT-Ia-1 and SAT-Ia-2, whereas very low levels of SAT-Ib-1 and SAT-Ib-2
brenda
additional information
-
67NR cell
brenda
additional information
-
in B16 melanoma cells SAT-Ia is present
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Adenocarcinoma
GM3 synthase gene is a novel biomarker for histological classification and drug sensitivity against epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Arthritis, Experimental
Ganglioside GM3 has an essential role in the pathogenesis and progression of rheumatoid arthritis.
Blindness
Etiology of vision loss in ganglioside GM3 synthase deficiency.
Blindness, Cortical
Cutaneous dyspigmentation in patients with ganglioside GM3 synthase deficiency.
Carcinogenesis
Analysis of differentially expressed genes in human rectal carcinoma using suppression subtractive hybridization.
Carcinoma
Clinicopathologic evaluation of CDw75 antigen expression in colorectal adenocarcinomas.
Carcinoma
GM3 synthase gene is a novel biomarker for histological classification and drug sensitivity against epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
GM3 synthase gene is a novel biomarker for histological classification and drug sensitivity against epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Congenital Abnormalities
Mice lacking ganglioside GM3 synthase exhibit complete hearing loss due to selective degeneration of the organ of Corti.
Deafness
Mice lacking ganglioside GM3 synthase exhibit complete hearing loss due to selective degeneration of the organ of Corti.
Epilepsy
Cutaneous dyspigmentation in patients with ganglioside GM3 synthase deficiency.
Epilepsy
Disorders of phospholipids, sphingolipids and fatty acids biosynthesis: toward a new category of inherited metabolic diseases.
Epilepsy
Etiology of vision loss in ganglioside GM3 synthase deficiency.
Glioma
Sialyltransferase-1 in a human malignant glioma cell line. Kinetic characteristics and effect of human interferon-beta.
Graves Disease
Thyroid sialyltransferase mRNA level and activity are increased in Graves' disease.
lactosylceramide alpha-2,3-sialyltransferase deficiency
Cutaneous dyspigmentation in patients with ganglioside GM3 synthase deficiency.
lactosylceramide alpha-2,3-sialyltransferase deficiency
Disorders of phospholipids, sphingolipids and fatty acids biosynthesis: toward a new category of inherited metabolic diseases.
lactosylceramide alpha-2,3-sialyltransferase deficiency
Early growth and development impairment in patients with ganglioside GM3 synthase deficiency.
lactosylceramide alpha-2,3-sialyltransferase deficiency
Etiology of vision loss in ganglioside GM3 synthase deficiency.
Leukemia
Elevated mRNA level of hST6Gal I and hST3Gal V positively correlates with the high risk of pediatric acute leukemia.
Lung Neoplasms
GM3 synthase gene is a novel biomarker for histological classification and drug sensitivity against epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Melanoma
Microarray analysis of differentially expressed genes regulating lipid metabolism during melanoma progression.
Melanoma
Positive regulation of tumor necrosis factor-alpha by ganglioside GM3 through Akt in mouse melanoma B16 cells.
Neoplasms
Clinicopathologic evaluation of CDw75 antigen expression in colorectal adenocarcinomas.
Neoplasms
GM3 synthase gene is a novel biomarker for histological classification and drug sensitivity against epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Neuroblastoma
Valproic acid-mediated transcriptional regulation of human GM3 synthase (hST3Gal V) in SK-N-BE(2)-C human neuroblastoma cells.
Neurocutaneous Syndromes
A mutation in a ganglioside biosynthetic enzyme, ST3GAL5, results in salt & pepper syndrome, a neurocutaneous disorder with altered glycolipid and glycoprotein glycosylation.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Bieberich, E.; MacKinnon, S.; Silva, J.; Li, D.D.; Tencomnao, T.; Irwin, L.; Kapitonov, D.; Yu, R.K.
Regulation of ganglioside biosynthesis by enzyme complex formation of glycosyltransferases
Biochemistry
41
11479-11487
2002
Mus musculus
brenda
Basu, S.K.; Whisler, R.L.; Yates, A.J.
Effects of lectin activation on sialyltransferase activities in human lymphocytes
Biochemistry
25
2577-2581
1986
Homo sapiens, Rattus norvegicus
brenda
Higashi, H.; Basu, M.; Basu, S.
Biosynthesis in vitro of disialosylneolactotetraosylceramide by a solubilized sialyltransferase from embryonic chicken brain
J. Biol. Chem.
260
824-828
1985
Gallus gallus
brenda
Freischutz, B.; Saito, M.; Rahmann, H.; Yu, R.K.
Activities of five different sialyltransferases in fish and rat brains
J. Neurochem.
62
1965-1973
1994
Oreochromis mossambicus, Rattus norvegicus
brenda
Busam, K.; Decker, K.
Ganglioside biosynthesis in rat liver. Characterization of three sialyltransferases
Eur. J. Biochem.
160
23-30
1986
Rattus norvegicus
brenda
Iber, H.; van Echten, G.; Sandhoff, K.
Substrate specificity of alpha 2->3-sialyltransferases in ganglioside biosynthesis of rat liver Golgi
Eur. J. Biochem.
195
115-120
1991
Rattus norvegicus
brenda
Fishman, P.H.; Bradley, R.M.; Henneberry, R.C.
Butyrate-induced glycolipid biosynthesis in HeLa cells: properties of the induced sialyltransferase
Arch. Biochem. Biophys.
172
618-626
1976
Homo sapiens
brenda
Trinchera, M.; Pirovano, B.; Ghidoni, R.
Sub-Golgi distribution in rat liver of CMP-NeuAc GM3- and CMP-NeuAc:GT1b alpha 2->8sialyltransferases and comparison with the distribution of the other glycosyltransferase activities involved in ganglioside biosynthesis
J. Biol. Chem.
265
18242-18247
1990
Rattus norvegicus
brenda
Cambron, L.D.; Leskawa, K.C.
Inhibition of CMP-N-acetylneuraminic acid:lactosylceramide sialyltransferase by nucleotides, nucleotide sugars and nucleotide dialdehydes
Biochem. Biophys. Res. Commun.
193
585-590
1993
Gallus gallus
brenda
Trinchera, M.; Fabbri, M.; Ghidoni, R.
Topography of glycosyltransferases involved in the initial glycosylations of gangliosides
J. Biol. Chem.
266
20907-20912
1991
Rattus norvegicus
brenda
Melkerson-Watson, L.J.; Sweeley, C.C.
Purification to apparent homogeneity by immunoaffinity chromatography and partial characterization of the GM3 ganglioside-forming enzyme, CMP-sialic acid:lactosylceramide alpha 2,3-sialyltransferase (SAT-1), from rat liver Golgi [published erratum appears in J Biol Chem 1991 Oct 15;266(29):19865]
J. Biol. Chem.
266
4448-4457
1991
Rattus norvegicus
brenda
Melkerson-Watson, L.J.; Sweeley, C.C.
Special considerations in the purification of the GM3 ganglioside-forming enzyme, CMP-sialic acid:lactosylceramide alpha 2-3 sialyltransferase (SAT-1): effects of protease inhibitors on rat hepatic SAT-1 activity
Biochem. Biophys. Res. Commun.
175
325-332
1991
Rattus norvegicus
brenda
Melkerson-Watson, L.J.; Sweeley, C.C.
Special considerations in the purification of the GM3 ganglioside forming enzyme, CMP-sialic acid:lactosylceramide alpha 2-3 sialyltransferase (SAT-1): solubilization of SAT-1 with lauryldimethylamine oxide
Biochem. Biophys. Res. Commun.
172
165-171
1990
Rattus norvegicus
brenda
Preuss, U.; Gu, X.; Gu, T.; Yu, R.K.
Purification and characterization of CMP-N-acetylneuraminic acid:lactosylceramide (alpha 2-3) sialyltransferase (GM3-synthase) from rat brain
J. Biol. Chem.
268
26273-26278
1993
Rattus norvegicus
brenda
Gu, X.B.; Gu, T.J.; Yu, R.K.
Purification to homogeneity of GD3 synthase and partial purification of GM3 synthase from rat brain
Biochem. Biophys. Res. Commun.
166
387-393
1990
Rattus norvegicus
brenda
Burczak, J.D.; Fairley, J.L.; Sweeley, C.C.
Characterization of a CMP-sialic acid:lactosylceramide sialyltransferase activity in cultured hamster cells
Biochim. Biophys. Acta
804
442-449
1984
Mesocricetus auratus
brenda
Eppler, C.M.; Morré, D.J.; Keenan, T.W.
Ganglioside biosynthesis in rat liver: alteration of sialyltransferase activities by nucleotides
Biochim. Biophys. Acta
619
332-343
1980
Rattus norvegicus
brenda
Kadowaki, H.; Grant, M.A.
Relationship of membrane phospholipid composition, lactosylceramide molecular species, and the specificity of CMP-N-acetylneuraminate:lactosylceramide alpha 2,3-sialyltransferase to the molecular species composition of GM3 ganglioside
J. Lipid Res.
36
1274-1282
1995
Rattus norvegicus
brenda
Pohlentz, G.; Mokros, A.; Egge, H.
Cholesterol-containing lactose derived neoglycolipids serve as acceptors for sialyltransferases from rat liver Golgi vesicles
Glycoconjugate J.
13
147-152
1996
Rattus norvegicus
brenda
Osanai, T.; Watanabe, Y.; Sanai, Y.
Glycolipid sialyltransferases are enhanced during neural differentiation of mouse embryonic carcinoma cells, P19
Biochem. Biophys. Res. Commun.
241
327-333
1997
Mus musculus
brenda
Bobryshev, Y.V.; Golovanova, N.K.; Tran, D.; Samovilova, N.N.; Gracheva, E.V.; Efremov, E.E.; Sobolev, A.Y.; et al.
Expression of GM3 synthase in human atherosclerotic lesions
Atherosclerosis
184
63-71
2006
Homo sapiens
brenda
Golovanova, N.K.; Samovilova, N.N.; Gracheva, E.V.; Peklo, M.M.; Vlasik, T.N.; Sobolev, A.Y.; Jurchenko, Y.V.; Prokazova, N.V.
Development of antibody to human GM3 synthase and immunodetection of the enzyme in human tissues
Biochemistry
69
275-280
2004
Homo sapiens (Q9UNP4)
brenda
Choi, H.J.; Chung, T.W.; Kang, N.Y.; Kim, K.S.; Lee, Y.C.; Kim, C.H.
Transcriptional regulation of the human GM3 synthase (hST3Gal V) gene during monocytic differentiation of HL-60 cells
FEBS Lett.
555
204-208
2003
Homo sapiens
brenda
Chung, T.W.; Choi, H.J.; Lee, Y.C.; Kim, C.H.
Molecular mechanism for transcriptional activation of ganglioside GM3 synthase and its function in differentiation of HL-60 cells
Glycobiology
15
233-244
2005
Homo sapiens
brenda
Iwamori, M.; Iwamori, Y.
Changes in the glycolipid composition and characteristic activation of GM3 synthase in the thymus of mouse after administration of dexamethasone
Glycoconj. J.
22
119-126
2005
Mus musculus (O88829)
brenda
Yamashita, T.; Hashiramoto, A.; Haluzik, M.; Mizukami, H.; Beck, S.; Norton, A.; Kono, M.; Tsuji, S.; Daniotti, J.L.; Werth, N.; Sandhoff, R.; Sandhoff, K.; Proia, R.L.
Enhanced insulin sensitivity in mice lacking ganglioside GM3
Proc. Natl. Acad. Sci. USA
100
3445-3449
2003
Mus musculus
brenda
Berselli, P.; Zava, S.; Sottocornola, E.; Milani, S.; Berra, B.; Colombo, I.
Human GM3 synthase: a new mRNA variant encodes an NH2-terminal extended form of the protein
Biochim. Biophys. Acta
1759
348-358
2006
Homo sapiens, Homo sapiens (Q9UNP4)
brenda
Sohn, H.; Kim, Y.; Kim, H.; Kim, C.; Cho, E.; Kang, H.; Kim, N.; Kim, C.; Ryu, S.E.; Lee, J.; Ko, J.H.
Ganglioside GM3 is involved in neuronal cell death
FASEB J.
20
1248-1250
2006
Mus musculus (O88829)
brenda
Wang, Z.; Sun, Z.; Li, A.V.; Yarema, K.J.
Roles for UDP-GlcNAc 2-epimerase/ManNAc 6-kinase outside of sialic acid biosynthesis: modulation of sialyltransferase and BiP expression, GM3 and GD3 biosynthesis, proliferation, and apoptosis, and ERK1/2 phosphorylation
J. Biol. Chem.
281
27016-27028
2006
Homo sapiens
brenda
Choi, H.J.; Park, Y.G.; Kim, C.H.
Lactosylceramide alpha2,3-sialyltransferase is induced via a PKC/ERK/CREB-dependent pathway in K562 human leukemia cells
Mol. Cell
23
138-144
2007
Homo sapiens
brenda
Choi, H.J.; Park, Y.G.; Kim, C.H.
Lactosylceramide alpha2,3-sialyltransferase is induced via a PKC/ERK/CREB-dependent pathway in K562 human leukemia cells
Mol. Cells
23
138-144
2007
Homo sapiens
brenda
Kwon, H.Y.; Kang, N.Y.; Dae, H.M.; Kim, K.S.; Kim, C.H.; Do, S.I.; Lee, Y.
Valproic acid-mediated transcriptional regulation of human GM3 synthase (hST3Gal V) in SK-N-BE(2)-C human neuroblastoma cells
Acta Pharmacol. Sin.
29
999-1005
2008
Homo sapiens
brenda
Gu, Y.; Zhang, J.; Mi, W.; Yang, J.; Han, F.; Lu, X.; Yu, W.
Silencing of GM3 synthase suppresses lung metastasis of murine breast cancer cells
Breast Cancer Res.
10
R1
2008
Mus musculus
brenda
Prinetti, A.; Aureli, M.; Illuzzi, G.; Prioni, S.; Nocco, V.; Scandroglio, F.; Gagliano, N.; Tredici, G.; Rodriguez-Menendez, V.; Chigorno, V.; Sonnino, S.
GM3 synthase overexpression results in reduced cell motility and in caveolin-1 upregulation in human ovarian carcinoma cells
Glycobiology
20
62-77
2010
Homo sapiens
brenda
Uemura, S.; Yoshida, S.; Shishido, F.; Inokuchi, J.
The cytoplasmic tail of GM3 synthase defines its subcellular localization, stability, and in vivo activity
Mol. Biol. Cell
20
3088-3100
2009
Homo sapiens, Mus musculus
brenda
Gracheva, E.V.; Samovilova, N.N.; Golovanova, N.K.; Kashirina, S.V.; Shevelev, A.; Rybalkin, I.; Gurskaya, T.; Vlasik, T.N.; Andreeva, E.R.; Prokazova, N.V.
Enhancing of GM3 synthase expression during differentiation of human blood monocytes into macrophages as in vitro model of GM3 accumulation in atherosclerotic lesion
Mol. Cell. Biochem.
330
121-129
2009
Homo sapiens
brenda
Yoshikawa, M.; Go, S.; Takasaki, K.; Kakazu, Y.; Ohashi, M.; Nagafuku, M.; Kabayama, K.; Sekimoto, J.; Suzuki, S.; Takaiwa, K.; Kimitsuki, T.; Matsumoto, N.; Komune, S.; Kamei, D.; Saito, M.; Fujiwara, M.; Iwasaki, K.; Inokuchi, J.
Mice lacking ganglioside GM3 synthase exhibit complete hearing loss due to selective degeneration of the organ of Corti
Proc. Natl. Acad. Sci. USA
106
9483-9488
2009
Mus musculus
brenda
Kim, S.J.; Chung, T.W.; Choi, H.J.; Kwak, C.H.; Song, K.H.; Suh, S.J.; Kwon, K.M.; Chang, Y.C.; Park, Y.G.; Chang, H.W.; Kim, K.S.; Kim, C.H.; Lee, Y.C.
Ganglioside GM3 participates in the TGF-beta1-induced epithelial-mesenchymal transition of human lens epithelial cells
Biochem. J.
449
241-251
2013
Homo sapiens (Q9UNP4)
brenda
Gracheva, E.; Samovilova, N.; Golovanova, N.; Piksina, G.; Shishkina, V.; Prokazova, N.
Activation of ganglioside GM3 biosynthesis in human blood mononuclear cells in atherosclerosis
Biochemistry
6
266-272
2012
Homo sapiens
-
brenda
Song, N.; Kim, S.J.; Kwon, H.Y.; Son, S.W.; Kim, K.S.; Ahn, H.B.; Lee, Y.C.
Transcriptional activation of human GM3 synthase (hST3Gal V) gene by valproic acid in ARPE-19 human retinal pigment epithelial cells
BMB Rep.
44
405-409
2011
Homo sapiens, Homo sapiens (Q9UNP4)
brenda
Paccalet, T.; Coulombe, Z.; Tremblay, J.P.
Ganglioside GM3 levels are altered in a mouse model of HIBM: GM3 as a cellular marker of the disease
PLoS ONE
5
e10055
2010
Mus musculus, Mus musculus (O88829)
brenda
HOME
login
history
all enzymes
BRENDA home
History
Enzyme Nomenclature
New: Word Map on EC 2.4.99.9
COMMENTARY
2.4.99.9-RECOMMENDED NAME
----REACTION TYPE
top
Information
